Velasco C E, Jackson E K, Morrow J A, Vitola J V, Inagami T, Forman M B
Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2107.
Cardiovasc Res. 1993 Jan;27(1):121-8. doi: 10.1093/cvr/27.1.121.
Intravenous adenosine decreases infarct size in experimental models of myocardial ischaemia/reperfusion. Ischaemia/reperfusion is associated with a significant increase in cardiac release of endothelin. The effect of cardioprotective doses of adenosine on endothelin release was explored in dogs undergoing 90 min coronary occlusion and 210 min reperfusion.
Dogs were assigned to intravenous adenosine in a dose of 0.15 mg.kg-1.min-1 (n = 12) or control (n = 11) during the first 150 min reperfusion. Serial endothelin levels were obtained from the coronary sinus and aortic blood and measured by radioimmunoassay.
Adenosine significantly reduced infarct size expressed as a percent of the risk region (28.8 6% v 14.4 2%; p = 0.03). A similar increase in aortic and coronary sinus blood endothelin was observed in both groups during temporary occlusion. A significant transcardiac increase in endothelin levels was present in the control group 60 min after reperfusion whereas no increase occurred in the adenosine treated group [control 5.6(SEM 1.9) v adenosine -0.2(1.4) pg.ml-1; p = 0.02]. Similarly, intravenous adenosine tended to prevent the increase in myocardial endothelin production seen in control animals during the early reperfusion period [control 280(146) v adenosine -57(55) pg.min-1; p = 0.05]. Endocardial blood flow in the ischaemic zone 210 min after reperfusion was significantly higher in the adenosine group, at 0.60(0.02) v 0.38(0.02) ml.min-1.g-1; p < 0.05. A significant correlation between endothelin levels, endocardial flow and infarct size was observed in the control group 3 h after reperfusion: r = 0.73, p = 0.02; r = 0.62, p = 0.03 respectively. This relationship was absent in animals treated with adenosine.
Intravenous adenosine suppresses the release of endothelin from the previously ischaemic myocardium during the early reperfusion period. This effect may in part contribute to the improvement by adenosine in postischaemic microcirculatory flow resulting in attenuation of the "no reflow" phenomenon.
在心肌缺血/再灌注实验模型中,静脉注射腺苷可减小梗死面积。缺血/再灌注与心脏内皮素释放显著增加有关。本研究探讨了给予心脏保护剂量的腺苷对经历90分钟冠状动脉闭塞和210分钟再灌注的犬内皮素释放的影响。
在再灌注的前150分钟内,将犬分为静脉注射腺苷组(剂量为0.15mg·kg-1·min-1,n = 12)或对照组(n = 11)。从冠状窦和主动脉血中获取系列内皮素水平,并通过放射免疫测定法进行测量。
以危险区域的百分比表示,腺苷显著减小了梗死面积(28.8±6%对14.4±2%;p = 0.03)。在临时闭塞期间,两组的主动脉和冠状窦血内皮素均有类似增加。再灌注60分钟后,对照组的心内膜内皮素水平有显著的跨心脏增加,而腺苷治疗组未增加[对照组5.6(标准误1.9)对腺苷组-0.2(1.4)pg·ml-1;p = 0.02]。同样,静脉注射腺苷倾向于防止对照组动物在再灌注早期出现的心肌内皮素生成增加[对照组280(146)对腺苷组-57(55)pg·min-1;p = 0.05]。再灌注210分钟后,腺苷组缺血区的心内膜血流显著更高,分别为0.60(0.02)对0.38(0.02)ml·min-1·g-1;p < 0.05。再灌注3小时后,对照组内皮素水平、心内膜血流与梗死面积之间存在显著相关性:r = 0.73,p = 0.02;r = 0.62,p = 0.03。腺苷治疗的动物不存在这种关系。
静脉注射腺苷可抑制再灌注早期先前缺血心肌的内皮素释放。这种作用可能部分有助于腺苷改善缺血后微循环血流,从而减轻“无复流”现象。